厄洛替尼对化疗失败的晚期非小细胞肺癌的疗效及安全性研究  

The efficacy and safety of Erlotinib in chemotherapy resistant advanced non-small cell lung cancer(NSCLC) patients

作　　者：任英红 刘海洋[2] 刘文超[3] 张红梅[3] 

机构地区：[1]商洛市中心医院肿瘤中心,陕西商洛726000 [2]商洛市中心医院磁共振室,陕西商洛726000 [3]第四军医大学西京医院肿瘤中心,陕西西安710032

出　　处：《现代肿瘤医学》2012年第9期1841-1843,共3页Journal of Modern Oncology

基　　金：吴阶平医学基金会临床科研专项基金(编号:320.6799.1134)

摘　　要：目的:观察厄洛替尼对化疗失败的晚期非小细胞肺癌的疗效及安全性。方法:82例既往化疗失败的Ⅲ-Ⅳ期非小细胞肺癌(NSCLC)患者,均EFGR监测阳性,给予单用厄洛替尼150 mg/d,服药至病情进展或出现不能耐受的不良反应,观察厄洛替尼的疗效和不良反应,对其生存期进行分析。结果:82例患者均可评价疗效,中位治疗时间为5个月(1-14个月);客观有效率为36.5%;疾病控制率为56.1%。性别、吸烟史、PS评分及病理类型,临床分期对疗效无统计学关联。中位肿瘤进展时间(214±26)d;中位生存期(375±21)d,1年生存率30.3%,其中肺腺癌疗效较好占30%。最常见的不良反应为皮疹(21.9%)。结论:厄洛替尼对化疗失败的中晚期非小细胞肺癌疗效确切,且不良反应轻,耐受性好。Objective： To investigate the antitumor effect, adverse reactions of erlotinih in treating patient with chemotherapy failure advanced non - small eel1 lung cancers. Methods： Eighty - two patients with Ⅲ to IV NSCLC who had previously treated with 4 - 6 cycles of platinum - based chemotherapy and advanced EGFR mutation - posi-tive, were enrolled into the study. The regimen was oral intake of erlotinib 150mg once daily. Retrospective analysis of the efficacy, side effects and toxicity and survival conditions for erlotinib in treatment of the 82 cases were performed. Results：All the 82 patients can be evaluated. Among 82 cases RR was 36.5% and DCR 56.1%. The median treat-ment time was 5 months （ 1 - 14 months）. Gender, pathology type, history of smoking and PS were not related to RR. The median survival time was （375 ±21）d; The median time of progression was （214 ~：26）d;1 year survival rate was 30.3 %. The most common adverse events were rash （21.9%）. Conclusion： Erlotinib was effective and safe for patients with advanced non - small cell lung cancer who failed prior chemotherapy. Erlotinib adverse reaction was light and good tolerant.

关 键 词：厄洛替尼 非小细胞肺癌 表皮生长因子受体 

分 类 号：R734.21[医药卫生—肿瘤]